NextGenGENERATION 01 / ONE TARGET
Compounded semaglutide, clearly explained.
This page explains semaglutide and compounding: making a medicine to order. Products approved by the U.S. Food and Drug Administration (FDA) exist. Compounded semaglutide is not FDA-approved. The ingredient name alone does not describe a product’s approval or its suitability for a person.
TARGET STUDY / 01
GLP-1
01
The first step on the target ladder.
Semaglutide is a peptide, a short chain of protein building blocks. It acts on the GLP-1 receptor. A receptor is a part of a cell that receives a signal. GLP-1 is the name of a natural hormone signal in the body.
Semaglutide is a man-made, altered copy of that hormone. The technical term is receptor agonist: a compound that activates a receptor. In this guide, that makes it our one-target generation.
Tirzepatide acts on two receptor types. Retatrutide, still investigational, acts on three. Those counts help explain the designs. A higher count does not decide which medicine, if any, is appropriate for someone.
02
Approval belongs to a specific medicine.
FDA is short for the U.S. Food and Drug Administration. Its approval concerns a finished medicine. The existence of an approved semaglutide product does not give approval to every product called semaglutide.
Compounding means making a medicine to order. Compounded semaglutide is not FDA-approved. The FDA does not check the safety, quality or effectiveness of a compounded medicine before it is sold.
A pharmacy licence is also different from product approval. Compounded medicines are not FDA-approved. A pharmacy licence does not change that status.
03
Compounding has limits.
Compounding can address a patient's medical need that an approved product cannot meet. The law limits routine copies of medicines already available. A licensed provider must consider the individual need and the rules that apply.
A useful question is: What exact product is being considered, and why? Other questions include which pharmacy would be involved and what follow-up the provider would arrange. This page cannot answer those questions for an individual.
04
A label cannot review your health.
A research-only sale may carry the words “not for human use.” That order does not include a provider assessing your health. The FDA has warned about unapproved semaglutide sold with research labels and about products of unknown quality.
A clinical review concerns a person as well as a product. Medical history, other medicines and pregnancy plans can be relevant. A provider decides whether care is appropriate; finding a familiar ingredient name online does not settle it.
05
The linked U.S. route starts with review.
Promise prescribes semaglutide and tirzepatide now through licensed U.S. providers. A provider reviews every request and decides whether to prescribe. Not everyone qualifies.
A licensed U.S. provider reviews each request and makes the prescription decision. A product choice does not guarantee a prescription.
Medications are prepared by licensed U.S. compounding pharmacies. Compounded medications are not FDA-approved.
Promise is for U.S. patients only. Availability varies by state and by treatment.
Promise is LegitScript-certified. This is a private check of business standards, not FDA approval or a rating of medical care.
06
Reading behind this page.
- Semaglutide: approved product information
Records the GLP-1 target and the status of a specific approved semaglutide product.
- FDA: risks of compounded medicines
Explains that compounded medicines do not receive FDA approval before they are sold.
- FDA: what compounding means
Explains medicines made to order and how they differ from FDA-approved products.
The next step is a question about care.
Promise prescribes semaglutide and tirzepatide now through licensed U.S. providers. A provider reviews every request and decides whether to prescribe. Not everyone qualifies.